Resource-sparing and cost-effective strategies in current management of breast cancer

被引：6

作者：

Munshi, Anusheel ^{[1
]}

机构：

[1] Tata Mem Hosp, Dept Radiat Oncol, Bombay 400012, Maharashtra, India

来源：

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | 2009年 / 5卷 / 02期

关键词：

Breast cancer; resource sparing; cost effective; ADJUVANT CHEMOTHERAPY; PREMENOPAUSAL PATIENTS; POSTMENOPAUSAL WOMEN; CONSERVING THERAPY; RADIATION-THERAPY; RANDOMIZED-TRIAL; TAMOXIFEN; TRASTUZUMAB; LONG; RADIOTHERAPY;

D O I：

10.4103/0973-1482.52797

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the leading cause of death in women throughout the world. There have been significant advances in the practice of breast oncology over the past few years. However, most of these advances have an associated price tag or are resource intensive. The present article discusses means to achieve cost-effectiveness in the treatment of breast cancer, while retaining the benefits of the modern anticancer approaches.

引用

页码：116 / 120

页数：5

共 44 条

[31] Punglia RS, 2007, J CLIN ONCOL, V25
[32] Reddy NJ, 2007, CLIN PHARMACOL THER, V81, pS16
[33] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Romond, EH
Perez, EA
Bryant, J
Suman, VJ
Geyer, CE
Davidson, NE
Tan-Chiu, E
Martino, S
Paik, S
Kaufman, PA
Swain, SM
Pisansky, TM
Fehrenbacher, L
Kutteh, LA
Vogel, VG
Visscher, DW
Yothers, G
Jenkins, RB
Brown, AM
Dakhil, SR
Mamounas, EP
Lingle, WL
Klein, PM
Ingle, JN
Wolmark, N
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1673 - 1684
[34] Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease:: A randomized phase III trial of the international atomic energy agency (IAEA)
Salazar, OM
Sandhu, T
da Motta, NW
Escutia, MAP
Lanzós-Gonzales, E
Mouelle-Sone, A
Moscol, A
Zaharia, M
Zaman, S
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (03): : 765 - 775
[35] A shorter fractionation schedule for postlumpectomy breast cancer patients
Shelley, W
Brundage, M
Hayter, C
Paszat, L
Zhou, S
Mackillop, W
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (05): : 1219 - 1228
[36] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Slamon, DJ
Leyland-Jones, B
Shak, S
Fuchs, H
Paton, V
Bajamonde, A
Fleming, T
Eiermann, W
Wolter, J
Pegram, M
Baselga, J
Norton, L
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) : 783 - 792
[37] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE
SLAMON, DJ
CLARK, GM
WONG, SG
LEVIN, WJ
ULLRICH, A
MCGUIRE, WL
[J]. SCIENCE, 1987, 235 (4785) : 177 - 182
[38] TIME-DOSE FACTORS IN RADIOTHERAPY - A REVIEW OF THE HUMAN DATA
THAMES, HD
BENTZEN, SM
TURESSON, I
OVERGAARD, M
VANDENBOGAERT, W
[J]. RADIOTHERAPY AND ONCOLOGY, 1990, 19 (03) : 219 - 235
[39] TONGBAI R, 2008, AM J PATHOL, V10, P212
[40] TRAVIS K, 2005, JNCI-J NATL CANCER I, V97, P2

← 1 2 3 4 5 →